AU2003250685A1 - Methods of identifying selective beta-1-adrenergic receptor antagonists - Google Patents

Methods of identifying selective beta-1-adrenergic receptor antagonists

Info

Publication number
AU2003250685A1
AU2003250685A1 AU2003250685A AU2003250685A AU2003250685A1 AU 2003250685 A1 AU2003250685 A1 AU 2003250685A1 AU 2003250685 A AU2003250685 A AU 2003250685A AU 2003250685 A AU2003250685 A AU 2003250685A AU 2003250685 A1 AU2003250685 A1 AU 2003250685A1
Authority
AU
Australia
Prior art keywords
methods
receptor antagonists
adrenergic receptor
selective beta
identifying selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003250685A
Other versions
AU2003250685A8 (en
Inventor
Youngshil Pak
Daniela Rotin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children HSC
Original Assignee
Hospital for Sick Children HSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital for Sick Children HSC filed Critical Hospital for Sick Children HSC
Publication of AU2003250685A1 publication Critical patent/AU2003250685A1/en
Publication of AU2003250685A8 publication Critical patent/AU2003250685A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
AU2003250685A 2002-07-31 2003-07-31 Methods of identifying selective beta-1-adrenergic receptor antagonists Abandoned AU2003250685A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002396350A CA2396350A1 (en) 2002-07-31 2002-07-31 Methods of identifying selective .beta.-1-adrenergic receptor antagonists
CA2,396,350 2002-07-31
PCT/CA2003/001130 WO2004011018A2 (en) 2002-07-31 2003-07-31 Methods of identifying selective beta-1-adrenergic receptor antagonists

Publications (2)

Publication Number Publication Date
AU2003250685A1 true AU2003250685A1 (en) 2004-02-16
AU2003250685A8 AU2003250685A8 (en) 2004-02-16

Family

ID=30774592

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003250685A Abandoned AU2003250685A1 (en) 2002-07-31 2003-07-31 Methods of identifying selective beta-1-adrenergic receptor antagonists

Country Status (3)

Country Link
AU (1) AU2003250685A1 (en)
CA (1) CA2396350A1 (en)
WO (1) WO2004011018A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4933435B2 (en) 2004-09-14 2012-05-16 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト Bucindolol treatment method based on gene targeting
CN112575051A (en) * 2019-09-27 2021-03-30 泰州医药城国科化物生物医药科技有限公司 Cell screening model of beta 1 adrenergic receptor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203776B1 (en) * 1997-04-03 2001-03-20 University Technology Corporation Method for identifying adrenergic receptor antagonists having good tolerability
CA2259830A1 (en) * 1999-01-20 2000-07-20 Hsc Research And Development Limited Partnership Ras activator nucleic acid molecules, proteins and methods of use

Also Published As

Publication number Publication date
WO2004011018A3 (en) 2004-05-06
AU2003250685A8 (en) 2004-02-16
CA2396350A1 (en) 2004-01-31
WO2004011018A2 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
AU2003231513A1 (en) Pgd2 receptor antagonist
AU2003261392A1 (en) M3muscarinic acetylcholine receptor antagonists
IL165871A0 (en) Substituted quinoline CCR5 receptor antagonists
AU2003290700A1 (en) Farnesoid x receptor agonists
AU2003241836A1 (en) Lpa receptor antagonists
IL165841A0 (en) Mchir antagonists
AUPR833401A0 (en) G protein-coupled receptor antagonists
EP1536813A4 (en) Compositions and methods comprising protein activated receptor antagonists
AU2003255501A1 (en) Cxcr4 receptor antagonists
PL378753A1 (en) Ccr-3 receptor antagonists
MY143499A (en) Crf receptor antagonist and methods relating thereto
AU2003215549A1 (en) Mercaptoimidazoles as ccr2 receptor antagonists
AU2003267088A1 (en) Chemokine receptor antagonists as therapeutic agents
AU2003260072A1 (en) Antagonists of chemokine receptors
AU2003286251A1 (en) New bicyclic angiotensin ii agonists
AU2003300904A1 (en) Antagonists for human prolactin
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
AU2003240705A1 (en) Morpholinylmethylureas ccr-3 receptor antagonists
AU2003280675A1 (en) SELECTIVE HUMAN Beta3 ADRENALIN RECEPTOR AGONIST AGENT
AU2002359524A1 (en) P2x7 receptor antagonists
AU2003287219A1 (en) Il-8 receptor antagonists
GB0226227D0 (en) Receptors
GB0203412D0 (en) 5-HT 2B receptor antagonists
AU2003250685A1 (en) Methods of identifying selective beta-1-adrenergic receptor antagonists
AU2003247052A1 (en) Mcp-1 receptor antagonists and method of use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase